Protagonist Therapeutics, Inc.
General ticker "PTGX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.2B (TTM average)
Protagonist Therapeutics, Inc. follows the US Stock Market performance with the rate: 35.6%.
Estimated limits based on current volatility of 2.1%: low 84.67$, high 88.26$
Factors to consider:
- Total employees count: 126 as of 2024
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Lack of approved products, Geopolitical risks, Economic downturns and volatility, Regulatory and compliance, Strategic risks and growth management
- Current price 76.0% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [25.15$, 49.63$]
- 2025-12-31 to 2026-12-31 estimated range: [22.44$, 45.47$]
Financial Metrics affecting the PTGX estimates:
- Negative: with PPE of 9.4 at the end of fiscal year the price was very high
- Positive: Operating profit margin, % of 58.20 > 18.64
- Positive: 6.82 < Operating cash flow per share per price, % of 7.57
- Positive: Inventory ratio change, % of -4.17 <= -0.75
- Positive: Return on assets ratio (scaled to [-100,100]) of 26.98 > 6.04
- Negative: negative Industry operating cash flow (median)
- Positive: -14.38 < Investing cash flow per share per price, % of -12.31
- Positive: Shareholder equity ratio, % of 90.68 > 63.39
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term PTGX quotes
Long-term PTGX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $26.58MM | $60.00MM | $434.43MM |
| Operating Expenses | $157.95MM | $153.65MM | $181.59MM |
| Operating Income | $-131.37MM | $-93.65MM | $252.84MM |
| Non-Operating Income | $3.98MM | $14.70MM | $26.57MM |
| R&D Expense | $126.22MM | $120.16MM | $138.13MM |
| Income(Loss) | $-127.39MM | $-78.95MM | $279.41MM |
| Taxes | $0.00MM | $0.00MM | $4.22MM |
| Profit(Loss)* | $-127.39MM | $-78.95MM | $275.19MM |
| Stockholders Equity | $215.61MM | $336.68MM | $675.29MM |
| Assets | $247.93MM | $357.95MM | $744.73MM |
| Operating Cash Flow | $-108.14MM | $-70.24MM | $184.15MM |
| Capital expenditure | $0.80MM | $0.61MM | $1.35MM |
| Investing Cash Flow | $91.47MM | $-39.26MM | $-299.48MM |
| Financing Cash Flow | $18.84MM | $170.48MM | $25.85MM |
| Earnings Per Share** | $-2.60 | $-1.39 | $4.47 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.